<DOC>
	<DOCNO>NCT02838745</DOCNO>
	<brief_summary>Primary Objective To determine maximum tolerate dose ( MTD ) intrathoracic administration pemetrexed give conjunction cisplatin patient resectable malignant pleural mesothelioma MPM . Secondary Objectives To determine toxicity grade associate cytoreductive surgery Hyperthermic Intraoperative Chemotherapy HIOC cisplatin pemetrexed patient resectable MPM . To assess overall survival progression-free survival PD EPP HIOC cisplatin pemetrexed MPM Correlative Objectives To characterize pharmacokinetics pharmacodynamics pemetrexed administer hyperthermic intrathoracic lavage PD EPP To determine whether degree thymidylate synthase ERCC1 gene expression MPM tissue correlate clinical response pemetrexed .</brief_summary>
	<brief_title>Study Cytoreductive Surgery Hyperthermic Intraoperative Chemotherapy With Pemetrexed Cisplatin Malignant Pleural Mesotheliomas</brief_title>
	<detailed_description>TREATMENT PLAN PREOPERATIVE HYDRATION According observation , preoperative hydration reduces risk nephrotoxicity intrathoracic infusion hyperthermic cisplatin . Therefore , patient admit night surgery receive intravenous hydration . CYTOREDUCTIVE SURGERY Eligible patient undergo extrapleural pneumonectomy ( EPP ) pleurectomy/decortication ( PD ) Baylor College Medicine board-certified thoracic surgeon . Patients give ondansetron 8mg x 1 dose induction anesthesia , initiation chemotherapy lavage . The anti-emetics adjust grade III toxicity still encounter . Patients undergo cytoreductive surgery ( PD EPP ) curative intent . In event tumor remove investigator allow total 1 cm3 less disease one area . If tumor unresectable debulking obtain , patient receive additional treatment protocol . Mediastinal lymph node sample perform . In event diaphragm pericardium resect , reconstruct polytetrafluoroethylene ( PTFE ) . RENAL PROTECTION STRATEGY The investigator continue establish perioperative renal protection strategy minimize risk cisplatin-induced nephrotoxicity . Perioperative Intravenous Hydration : The patient admit night surgery intravenous hydration . During operation , anesthesiologist monitor urine output . At discretion , diuretic , renal dose dopamine , fluid challenge institute maintain urine output least 100 cc per hour . In immediate postoperative setting , patient aggressively hydrate ; pulmonary artery catheter use guide management . Cisplatin-induced diuresis ( 100 cc per hour ) replace crystalloid first 24 hour surgery follow rate : 1cc crystalloid per 1cc urine PD 0.5cc crystalloid per 1cc urine EPP . Amifostine Sodium Thiosulfate Per Protocol . HEATED INTRAOPERATIVE CHEMOTHERAPY PERFUSION The procedure follow : - After cancer resection complete , perfusion cannulae place within open hemithorax . - A total three temperature probe place within hemithorax upper abdomen ( via chest since diaphragm longer present PDs EPPs ) esophagus . - Another two temperature probe use monitor temperature solution circuit . - An open well create thoracotomy use Omni tract retractor , use monofilament suture skin edge retractor , enclose area plastic cover . - A slit plastic cover make large enough allow surgeon 's double-gloved hand hemithorax evenly distribute perfusate . The surgeon gently ( repeatedly ) manipulates expose area allow uniform distribution heat chemotherapy . - Pemetrexed cisplatin admix together 1 liter normal saline . The admixture pemetrexed/cisplatin stable 4 hour prepared deliver immediately use OR . The length pemetrexed/cisplatin lavage 1 hour . - A roller pump force heat chemotherapy chest abdomen inflow cannula pull via outflow cannula . - If perfusate solution fill chest cavity , one intact bag saline place chest cavity displace perfusate . In manner , chest cavity fill without dilute perfusate . - A heat exchanger keep fluid infuse 43-45 degree Celsius intrathoracic fluid 42 degree Celsius . - A smoke evacuator use pull air beneath plastic cover activate charcoal , prevent possible contamination air operate room chemotherapy aerosol . Pharmacokinetics draw per protocol . Dose Levels Cohort Pemetrexed Dose A 300 mg/m2 B 400 mg/m2 C 500 mg/m2 D 600 mg/m2 E 700 mg/m2 F 800 mg/m2 Stop Analyze Safety G 900 mg/m2 H 1000 mg/m2 Stop Analyze Safety The standard dose pemetrexed systemic administration 500 mg/m2 . However , pemetrexed previously study direct administration chest , initial cohort receive slightly low dose ensure method administer pemetrexed safe . Once safety establish low dos , investigator feel confident pemetrexed intrathoracic dose slightly high standard systemic dose ( 500 mg/m2 ) give safely . In animal model , high dos result systemic concentration pemetrexed ( correlate systemic toxicity ) potentially low intracavitary infusion systemic administration 2 . These high dos may result superior long-term clinical outcome . Schedule Assignment Dose Levels Patients enrol cohort 3 accord dose escalation/de-escalation rule specify . For purpose execute dose escalation scheme , toxicity assess 4 week treatment . Additional patient cohort enrol toxicity evaluable patient treat current dose complete observation period . In addition , investigator pause completion 800 mg/m2 , MTD reach , assure delay toxicity n't manifest . If MTD exceed high dose level , escalation schedule may expand . Dose limit toxicity ( DLT ) define : - Grade 4 treatment-related hematologic toxicity last 5 day grade 3 thrombocytopenia grade 3 4 bleed - Febrile neutropenia - Grade 3 great treatment relate non-hematologic toxicity follow exception : - Grade 3 diarrhea DLT patient compliant anti-diarrheal program consistent best clinical practice - Grade 3 4 nausea vomit DLT patient compliant antiemetic program consistent best clinical practice - Alopecia Supportive Care Guidelines All supportive measure consistent optimal patient care give throughout study . Duration Therapy Patients receive protocol therapy unless : 1 . Extraordinary medical circumstance : If time constraint protocol detrimental patient 's health , protocol treatment discontinue 2 . Patient withdraws consent 3 . There evidence progressive disease unacceptable toxicity 4 . The treat physician think change therapy would best interest patient Follow-up All patient , include discontinue protocol therapy early , follow oncologist primary care provider . The date death record .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histologically proven malignant pleural mesothelioma MPM consider resectable accord follow criterion : Confined one pleural space No chest wall invasion No transdiaphragmatic involvement No invasion mediastinal structure 2 . Age ≥ 18 year 3 . Eastern Cooperative Oncology Group performance status 01 ( Appendix A ) 4 . Adequate cardiopulmonary reserve define follow assess within 4 month study entry : Predicted postoperative forced expiratory volume FEV1 &gt; 1L Normal leave ventricular function ( Ejection Fraction EF ≥ 45 % ) right ventricular function No pulmonary hypertension note preoperative transthoracic echocardiography 5 . Must adequate hematologic , renal hepatic function define follow laboratory value ( complete within 7 day registration ) Hematologic : Hemoglobin ≥ 9.0 g/dL , absolute neutrophil count ( ANC ) ≥ 1500/mm3 , platelet count ≥ 100,000/mm Renal : Calculated creatinine clearance ≥ 60 mL/min The creatinine clearance CrCl determine CockcroftGault formula : Males : Creatinine Clearance CrCl ( mL ) /min ) = weight ( kg ) x ( 140age ) 72 x serum creatinine ( mg/dL ) Females : Creatinine Clearance CrCl ( mL ) /min ) = weight ( kg ) x ( 140age ) x 0.85 72 x serum creatinine ( mg/dL ) Hepatic : Total bilirubin &lt; 1.5 time upper limit institutional normal value ; Aspartate aminotransferase AST ( Serum glutamic oxaloacetic transaminase SGOT ) alanine aminotransferase ALT ( Serum glutamic pyruvic transaminase SGPT ) &lt; 3 time upper limit institutional normal Coagulation : international normalized ratio INR ≤ 1.5 patient utilizing systemic anticoagulation part medical regimen 6 . Women child bear potential sexually active male must use accepted effective nonhormonal method contraception 7 . Patients must deem investigator fully recover acute late effect prior surgery , radiotherapy , antineoplastic therapy 8 . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 9 . The ability interrupt nonsteroidal antiinflammatory drug NSAIDS 2 day ( 5 day longacting NSAIDs ) , day , 2 day follow administration Pemetrexed . 10 . The ability take folic acid , Vitamin B12 , dexamethasone accord protocol . 1 . Not pregnant breastfeed drug use study Pregnancy Category D ( clear evidence risk pregnancy ) . A negative pregnancy test require within 14 day registration pre perimenopausal ( i.e. , last menstrual period within one year registration ) woman . 2 . Patients history another neoplasm , exception nonmetastatic , nonmelanoma skin cancer , carcinoma situ cervix , cancer cure surgery small field radiotherapy , within 5 year registration exclude . 3 . Patients uncontrolled cardiovascular disease ( history hospitalization acute myocardial infarction , arrhythmia , congestive heart failure within 3 month prior registration ) exclude 4 . Registered patient active infection fever ≥ 38.5°C within 3 day first schedule day protocol initiation exclude infection and/or fever resolve . 5 . Any medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result . 6 . Inability interrupt use nonsteroidal antiinflammatory drug ( NSAIDS ) 7 . Peripheral neuropathy Grade 2 ( Common Terminology Criteria Adverse Events CTCAE ) 8 . Systemic chemotherapy within 4 week registration 9 . Prior Allergies : History allergic reaction attribute compound similar chemical biologic composition cisplatin pemetrexed 10 . Presence third space fluid control drainage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>